

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 7/02	A1	(11) International Publication Number: WO 99/07834 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/GB98/02387 (22) International Filing Date: 7 August 1998 (07.08.98) (30) Priority Data: 9716611.0 7 August 1997 (07.08.97) GB (71) Applicant (for all designated States except US): CANTAB PHARMACEUTICALS RESEARCH LIMITED [GB/GB]; 184 Cambridge Science Park, Milton Road, Cambridge CB4 4GN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): JOHNSTON, Michael, Denis [GB/GB]; Jesmond Dene, 9 The Crescent, Impington, Cambridge CB4 4NY (GB). O'KEEFFE, Roderic, Simon [GB/GB]; 65 Loompits Way, Saffron Walden, Essex CB11 4DN (GB). (74) Agents: O'BRIEN, Caroline, J. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: RECOVERY OF VIRUS FROM CELL CULTURE USING A HYPERTONIC SALT SOLUTION (57) Abstract A process of harvesting a herpesvirus from a cell culture infected therewith comprises treating said culture with a hypertonic aqueous salt solution to yield a virus suspension, e.g. to give improved yield of virus for live virus vaccine where otherwise cell-disruption might be used to harvest the virus by disrupting virus-infected cells. The harvesting step can be followed e.g. by nuclease treatment, diafiltration and lyophilisation.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RECOVERY OF VIRUS FROM CELL CULTURE USING A HYPERTONIC SALT SOLUTION

Field of the Invention:

5 This invention relates to the production of viruses and to the harvesting of virus preparations from virus-infected cell cultures, for example for experimental and therapeutic purposes, e.g. for the production of virus vaccines. In particular aspects the invention relates to methods and arrangements for the production of herpesviruses. Other aspects of the invention will be apparent from the description given below.

10

Background of the invention and Prior Art

Several methods are known for producing live virus preparations, e.g. herpesvirus preparations, for vaccine and other purposes.

15

For example, US 3,985,615 (Osaka Res Foundation: T Kubo et al) shows production of live attenuated varicella virus for vaccine use by culture comprising passage in guinea pig primary embryonic tissue cells. US 5,024,836 (Merck: WJ McAleer et al) relates to production of lyophilized vaccine preparations based thereon.

20

DD-209738 (Cent Cerc Bioprep: IV Patrascu) illustrates production of another type of herpesvirus, for use as vaccine against Marek's disease is produced by (a) culturing specific-pathogen-free chicken embryo cells on dextran microspheres; (b) inoculating the culture at 80% confluence with turkey herpes virus strain FC-126 (clone 1, IIb); (c) collecting the infected cells in SPGA medium (sucrose, phosphate, glutamate, bovine albumin fraction V) when the cytopathic effect is 80%; (d) subjecting the suspension to three ultrasonic pulses of 1 minute duration at 2 minute intervals and centrifuging it to recover a first crop of vaccine; (e) 25 resuspending the sediment in SPGA medium and repeating step (d) to obtain a second crop of vaccine (to increase the vaccine yield by almost 20%); (f) freezing the combined vaccines at -100 deg.C prior to determining the virus titre; and (g) diluting with SPGA medium and freeze drying.

30

35

JP06234659-A (ZH Handai Biseibutsu Kenkyukai) describes, in an example, production of herpesviral vaccine on human diploid fibroblast MRC-5 cells cultured in MEM medium at 37 deg.C; comprising inoculation of varicella virus Oka strain seed virus at a MOI of 0.03 to MRC-5 cells and culture at 37 deg.C for 2 days. Virus is then suspended in a solution 40 containing 6.4g NaCl, 0.16g KCl, 2.3g Na₂HPO₄·12H₂O, 0.16g KH₂PO₄, 50.0g

sucrose, 1.0g Na L-glutamate, 2.0g gelatin, 25.0g gelatin hydrolysate and 0.1g EDA-3Na per l.

5 EP 0 573 107, US 5,360,736 and US 5,607,852 (Merck: PA Friedman et al) describe processes for production of attenuated varicella zoster virus vaccine, including a process for preparing live, attenuated, cell-free varicella-zoster virus (VZV) vaccine that comprises: (a) Culturing VZV infection-susceptible cells, selected from human diploid cells, to
10 confluency in monolayer culture, under conditions of sufficiently high nutrition to achieve a high degree of cell replication, and supplying a non-metabolizable disaccharide; (b) infecting the cells cultured according to step (a) at as close to the point of confluency as possible with as high a multiplicity of infection of VZV-infected cells as practical; (c)
15 maintaining the VZV-infected culture in a state of high nutrition for about 22-96 hours and harvesting at the point of peak infectious VZV production; (d) washing the VZV-infected culture with a physiologic solution, optionally containing a lysosomotropic agent, such as ammonium chloride or chloroquine, prior to harvesting the VZV infected cells; (e) Harvesting the VZV infected
20 cells into a minimal volume of a stabilizing solution and either disrupting the cells immediately or freezing the cells for later disruption; (f) Disrupting the VZV-infected cells to optimally release cell-associated VZV, and removing cellular debris, to provide a cell-free VZV preparation. The process discloses use of cell densities of up to ca. 500,000 cells/cm² in conventional culture vessels. The process is proposed for mass production
25 of live vaccine. Appropriate nutrient medium for growing cells in monolayer culture in that connection is described as consisting essentially of SFRE-2 medium supplemented with between 0.2 mg/mL and 0.4 mg/mL soybean lipid, the cells being selected from MRC-5 cells, WI-38 cells and Vero cells.

30 WO 92/05263 (Immunology Ltd: SC Inglis et al) and WO 94/21807 (Cantab Pharmaceuticals Research: Inglis et al) are illustrative of the provision of recombinant cells and culture methods for producing genetically disabled herpesvirus such as herpes simplex virus for vaccine purposes.

35 It remains desirable to provide methods for treatment of virus-containing preparations, capable of contributing to the manufacture of virus preparations in good yield and purity.

SUMMARY AND DESCRIPTION OF THE INVENTION

40 According to one aspect of the present invention, a cell culture

infected with a herpesvirus can be treated to yield a virus suspension by a harvesting incubation with a hypertonic aqueous salt solution. The salt solution can be contacted with the cell culture to yield a liquid containing useful virus content and a much reduced content of cells or cell debris by comparison with (for example) the product of ultrasonic disruption. This process can for example be particularly applicable to give an improved yield of virus for the manufacture of live virus vaccine in a case where otherwise a cell-disruption step might be used to harvest virus by disrupting virus-infected cells of a virus-producing cell culture.

10

Many pharmaceutically acceptable salts are suitable and acceptable for this purpose, for example sodium chloride, sodium sulphate, potassium chloride, and others. Preferably the salt solution can comprise sodium chloride at for example about 0.8 to 0.9 M concentration or above. If sodium sulphate is used, concentration can preferably be about 0.4M or above. Other salts can be used, if desired at similar osmolarity or ionic strength to the concentrations indicated above. The virus can often stand up to 1M or 2M salt concentration but in each case, it is preferred not to go too far above the indicated concentration, so as to avoid excessive uptake of protein into the saline liquid. Buffering and other constituents can be chosen suitably in accordance with normal practice for handling the viruses concerned.

15

20

The harvesting incubation can be carried out with gentle agitation, and preferably is carried out in such a way as to involve no or minimal cell disruption. The cell culture to be treated to the harvesting incubation can be for example a monolayer culture or a microcarrier culture or a roller-bottle culture.

25

30

The harvesting salt solution can be buffered and maintained at a pH and temperature in themselves suitable for the culture of the virus-infected cells, e.g. about pH 7 and advantageously about 34 deg.C. for herpes simplex virus.

35

Contact time between the cultured cells and the harvesting liquid is not specially critical and can for example be in the range of about 2-24 hours. It has been found in connection with certain examples that for example about 4 hours contact time is preferable because it can offer good yield with acceptably low levels of cellular protein.

40

After contact between the cultured infected cells and the harvesting liquid, the liquid containing the harvested virus particles. can be separated by decantation or any other suitable method: the cultured cells themselves can be allowed to remain attached to the surface on which they were cultured, and can be discarded after the separation of the harvesting liquid.

The harvesting liquid can then if desired be treated by filtration and/or centrifugation to remove residual cells.

Desirably, the harvested preparation can be diluted or dia-filtered to approximately isotonic concentration, e.g. about 138 mM in sodium chloride.

According to a further aspect of the invention, the virus preparation harvested in this way can be treated with nuclease enzyme to reduce any content of contaminating nucleic acid to acceptable levels.

The diluted liquid can for example be treated with Benzonase (TM) nuclease enzyme, to degrade free nucleic acids (importantly DNA, and usually also RNA) at up to about 50 units/ml in the presence of about 2-10 mM magnesium ion, either for up to about 1 hour at from about 4 deg.C to room temperature.

The level of nuclease enzyme and other protein can then be reduced for example by dia-filtration against a suitable formulation buffer, through a membrane with a virus-retaining, e.g. 500kD, exclusion limit.

After these treatments the harvested virus can be transferred to a desired carrier liquid and frozen, lyophilised or otherwise stabilised in any suitable manner.

Processes according to examples of the invention can offer particular advantage in connection with highly cell-associated viruses, i.e. those viruses having a particularly high degree of cell association in culture, for example herpes simplex virus type 2 (HSV-2), pseudorabies virus (PRV), turkey herpesvirus and varicella zoster virus (VZV). With certain herpesviruses and culture conditions (e.g. with herpes simplex virus type 1 (HSV-1)) there can be a substantial spontaneous release of virus from the infected cells into the cell culture liquid, so that application of a

process according to an example of the present invention can sometimes here be unnecessary and accordingly such examples of the invention are less preferred.

5 The invention can be applied with any appropriate adaptations of detail as will be readily accessible to those skilled in the art, to herpesviruses of various types, including for example wild-type herpes simplex virus and genetically disabled herpes viruses such as herpes simplex virus, and for example other herpes viruses as mentioned in the documents
10 cited herein.

 The virus preparations obtained by the use of processing steps as described herein can be further processed and made part of pharmaceutical compositions e.g. with per-se conventional ingredients of virus vaccines.

15 The invention is further described and illustrated by the following non-limitative example.

EXAMPLE:

20 A process according to an example of the invention, for harvesting and purifying virus particles, can make use of a culture of Vero cells infected with HSV-2, grown essentially in known manner in conventional culture medium contained in roller bottles at about 100ml of medium per bottle. The culture medium, cell type and culture conditions can be for example as
25 follows:

 The Vero cells can be passaged at 2×10^7 cells per roller bottle. Culture can be carried out using DMEM medium with 4.5 g/l glucose without sodium pyruvate and with Glutamax-1 (TM) (L-alanyl-L-glutamine), 862 mg/l. Incubation can be carried out for example at about 37 deg.C and for about
30 120 hours (5 days). Confluent cell cultures can then be infected with HSV-2 at a multiplicity of infection of about 0.01, by diluting the virus in DMEM to the level where 1 ml is added to each roller bottle which is then returned to the roller-incubation apparatus at about 34-37 deg.C. When cytopathic effect is observed to be 80-100%, e.g. 65-72 hours after
35 infection, the roller bottles can be treated as ready for virus harvest.

 The culture medium can be decanted from each bottle and replaced by 10ml per bottle of a buffered sodium chloride solution (about 0.8-0.9M) containing 0.01M sodium citrate pH 7.0. The cells in the roller bottle in contact with this buffered sodium chloride solution can be rolled and
40 incubated at about 34 deg.C for about 4 hours.

The cultured cells themselves in the roller bottle can largely remain attached to the bottle surface and can be discarded after separation of the liquid containing the harvested virus particles.

5 The liquid in the bottle, comprising the buffered saline and material from the cell culture in suspension, including virus, can be removed by pipette and centrifuged at about 3000 rpm in a Sorvall RT6000 (TM) centrifuge for about 10 minutes (e.g. at RCFmax about 1876). The cells in the pellet, and those remaining in the bottle, are discarded (under appropriate virus-containment conditions) and the supernatant is taken by
10 pipette to the next step, which can be continuous flow centrifugation. Pre-filtration can be carried out with a 0.8 micron filter. The supernatant liquid from centrifugation can be diluted or diafiltered to a final concentration (in respect of sodium ion) of 138mM.

15 The diluted liquid can then be treated with Benzonase (TM) nuclease enzyme, to degrade free nucleic acids (importantly the enzyme used has DNase activity, and usually also, like Benzonase (TM), will have RNase activity) at up to about 50 units/ml in the presence of about 2-10 mM magnesium ion, e.g. for up to about 1 hour at a temperature from about 4 deg.C up to room temperature.

20 The reaction liquid can then be subjected to tangential cross-flow filtration (diafiltration) using a filter/membrane with a 500kD exclusion limit in a Filtron (TM) or other tangential crossflow device, using a recirculation rate of 1000 ml/min, a filtrate rate of 100 ml/min, and a backflush of 100 ml sodium citrate 0.01M pH 7.25 containing 138 mM sodium
25 chloride.

The retentate from the cross-flow ultrafiltration step can then be treated by diafiltration against 5-10 volumes of citrate/saline buffer to reduce the amount of nuclease enzyme, and the retentate is finally subjected to 0.2 micron (sterilising) filtration optionally preceded by filtration
30 with a filter of from about 0.45 micron to 5 micron, using the same buffer again, after making the liquid containing the virus preparation up to 20 mg/ml in a suitable stabilising protein, preferably human serum albumin at about 20 mg/ml. It can be useful to prewash the filters with a liquid containing the same stabilising protein in the same buffer, before using the
35 filters to treat the virus preparation.

The resulting product can be obtained as a suspension of virus particles in saline buffer and stabilising protein, in which the level of residual DNA can be satisfactorily low.

40 The yield from such a process has been found to be usefully good by

comparison with a process involving ultrasonic cell disruption to liberate virus particles, followed by separation of virus particles from cell debris.

5 The invention can be very usefully applied, for example in a preferred embodiment carried out according to the example described above, to the culture and harvesting of genetically disabled HSV-2 virus for vaccine use, which virus has a deletion in respect of the gH gene essential for production of infectious new virus particles, and is culturable on a cell line which is based on Vero cells which have been made recombinant and able to express the viral gH gene which is missing from the viral genome, e.g. 10 as described in specifications WO 92/05263 and WO 94/21807 (and see also A Forrester et al, J Virol 66 (1992) 341-348, also H E Farrell et al, J Virol 68 (1994) 927-932) and C McLean et al. J Infect Dis 170 (1994) 1100-1109).

15 It can also be preferable, according to convenience, to culture the cells and viruses on various forms of microcarriers in per-se known manner, instead of in roller bottles.

20 The present invention and disclosure extend to the methods and compositions and the resulting products as described herein, and to modifications and variations of the features mentioned and described herein, including combinations and subcombinations thereof, and the documents cited herein are hereby incorporated by reference in their entirety for all purposes.

25

CLAIMS:

- 1: A process of harvesting a herpesvirus from a cell culture infected therewith, which comprises treating said culture with a hypertonic aqueous salt solution to yield a virus suspension.
- 2: A process according to claim 1, wherein the virus suspension is further treated to formulate it as a pharmaceutical preparation suitable for use as a virus vaccine.
- 3: A process according to claim 1 or 2, wherein the salt comprises sodium chloride at about 0.8 M concentration or above.
- 4: A process according to claim 1, 2 or 3 wherein the harvesting salt solution is buffered at a pH about 7 and temperature about 34 deg.C. for the harvesting of herpes simplex virus.
- 5: A process according to any of claims 1-4 wherein the harvested preparation is then diluted or dia-filtered to approximately isotonic concentration.
- 6: A process according to any of claims 1-5 wherein the harvested virus preparation is treated with nuclease enzyme.
- 7: A process according to claim 6 wherein the preparation after nuclease treatment is dia-filtered against a formulation buffer, through a membrane with a virus-retaining exclusion limit.
- 8: A process according to any preceding claim wherein the harvested virus, after transfer to a desired carrier liquid, is frozen, lyophilised or otherwise stabilised.
- 9: A process according to claim 1, wherein the virus comprises herpes simplex virus type 2 (HSV-2), pseudorabies virus (PRV), turkey herpesvirus or varicella zoster virus (VZV).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02387

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GÖTZE ET AL: "IMMUNOGENICITY AND PARTIAL PURIFICATION OF SOLUBLE H-2 ANTIGENS EXTRACTED WITH HYPERTONIC SALT" JOURNAL OF IMMUNOLOGY, vol. 112, no. 5, 1974, pages 1643-1651, XP002084064 see page 143 see abstract	1-9
A	US 5 204 257 A (DEBONVILLE DAVID A ET AL) 20 April 1993 see column 1, line 59 - column 2, line 29	1-9
A	EP 0 573 107 A (MERCK & CO INC) 8 December 1993 cited in the application see page 2, line 34 - line 57	1-9

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

11 November 1998

Date of mailing of the international search report

27/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02387

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5204257 A	20-04-1993	NONE	
EP 0573107 A	08-12-1993	US 5360736 A	01-11-1994
		AU 673167 B	31-10-1996
		AU 4392193 A	30-12-1993
		BG 99227 A	28-07-1995
		CA 2097019 A	05-12-1993
		CN 1082923 A	02-03-1994
		CZ 9403045 A	18-10-1995
		FI 945697 A	26-01-1995
		HU 71863 A	28-02-1996
		JP 2599552 B	09-04-1997
		JP 6172215 A	21-06-1994
		JP 9107958 A	28-04-1997
		MX 9303274 A	31-01-1994
		NO 944654 A	03-02-1995
		NZ 253527 A	25-09-1996
		SK 148094 A	11-07-1995
		WO 9324616 A	09-12-1993
		US 5607852 A	04-03-1997

Form PCT/ISA/210 (patent family annex) (July 1992)